PUBLISHED BY
Cäcilia Jäger, Matthias Niemann, Gideon Hönger, Caroline Wehmeier, Helmut Hopfer, Thomas Menter, Patrizia Amico, Michael Dickenmann, Stefan Schaub
PUBLISHED IN
HLA
PATIENTS
439
ABSTRACT
HIGHLIGHTS
· Study evaluates three molecular mismatch metrics—eplet mismatchcount, highly immunogenic eplets, and PIRCHE-II score—to classify renaltransplant rejection risk.
· Low- and high-risk groups were defined basedon whether all scores were below or above certain cut-offs.
· One-year rejection incidence was 12% in thelow-risk group and 33% in the high-risk group, showing a significantdifference.
· Internal validation confirmed the model’saccuracy in predicting clinical rejection, ATG-treated rejection, and de novoHLA-DSA.
· Findings suggest combining these molecularapproaches effectively stratifies rejection risk in standard renal transplantpatients.